Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SINGLE-DOSE BIOAVAILABILITY OF 2 EXTENDED-RELEASE LITHIUM-CARBONATE PRODUCTS
Autore:
KIRKWOOD CK; WILSON SK; HAYES PE; BARR WH; SARKAR MA; ETTIGI PG;
Indirizzi:
VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARM & PHARMACEUT,BOX 533 RICHMOND VA 23298 HAMPTON VET AFFAIRS HOSP HAMPTON VA 00000 SANDOZ PHARMACEUT INC E HANOVER NJ 00000 W VIRGINIA UNIV MORGANTOWN WV 00000
Titolo Testata:
American journal of hospital pharmacy
fascicolo: 4, volume: 51, anno: 1994,
pagine: 486 - 489
SICI:
0002-9289(1994)51:4<486:SBO2EL>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHARMACOKINETICS; FORMULATIONS;
Keywords:
ANTIMANIC AGENTS; BLOOD LEVELS; DOSAGE SCHEDULES; DRUGS, AVAILABILITY; EQUIVALENCY, GENERIC; EXCRETION; LITHIUM CARBONATE; SUSTAINED-ACTION MEDICATIONS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
32
Recensione:
Indirizzi per estratti:
Citazione:
C.K. Kirkwood et al., "SINGLE-DOSE BIOAVAILABILITY OF 2 EXTENDED-RELEASE LITHIUM-CARBONATE PRODUCTS", American journal of hospital pharmacy, 51(4), 1994, pp. 486-489

Abstract

The single-dose bioavailabilities of two extended-release lithium carbonate products and an immediate-release product were compared. Nonsmoking healthy volunteers ages 20-31 (n = 12) were randomly assigned to one of three groups and given three treatments, each separated by a one-week period. The treatments, which were given to each group in a different sequence, consisted of three 300-mg immediate-release lithium carbonate tab-lets (Lithotab), two 450-mg extended-release lithium carbonate tablets (Eskalith CR), and three 300-mg extended-release lithiumcarbonate tablets (Lithobid). Blood samples were collected just before drug administration and at intervals up to 48 hours after-ward. Urine was collected for 96 hours. Plasma and urine lithium concentrations were determined by flame-emission spectrophotometry, and lithium pharmacokinetic values and the cumulative urinary excretion of lithium werecomputed. Mean maximum plasma lithium concentration (C-max) differed significantly among all three lithium carbonate products. Eskalith CR produced a 40% lower C-max and lithobid a 25% lower C-max than Lithotab; Lithobid produced a 23% higher Cmax than Eskalith CR. Lithotab had a significantly shorter mean time to maximum plasma lithium concentration than either extended-release product. Much cumulative urinary excretion of lithium did not differ significantly among the three products. Two extended-release lithium carbonate products were not bioequivalent when given in single doses to healthy volunteers.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/07/20 alle ore 22:23:02